Related Experiment Video
Updated: Jun 26, 2026

Non-invasive Assessment of Microvascular and Endothelial Function
Published on: January 29, 2013
Microcirculatory dysfunction in hypertrophic cardiomyopathy with chest pain assessed by angiography-derived
Yahui Lu1,2, Zheng-Kai Xue1,2, Wenqing Gao1,2
1Department of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
Insights
Chest pain in hypertrophic cardiomyopathy (HCM) is linked to microvascular dysfunction. Angiography-derived microcirculatory resistance (AMR) revealed higher resistance in HCM patients, predicting adverse outcomes.
Area of Science:
- Cardiology
- Cardiovascular Physiology
Background:
- Chest pain is a common symptom in hypertrophic cardiomyopathy (HCM), often linked to myocardial ischemia without significant coronary artery stenosis.
- Microvascular dysfunction is increasingly recognized as a contributor to ischemia in HCM.
Purpose of the Study:
- To investigate microvascular dysfunction in HCM patients using angiography-derived microcirculatory resistance (AMR).
- To assess the correlation between AMR and clinical outcomes in HCM patients.
Main Methods:
- Retrospective analysis of HCM patients with chest pain and control patients.
- Calculation of AMR using angiography, a wire-free and adenosine-free index.
- Propensity score matching to balance demographic characteristics.
- Correlation analysis with echocardiography and follow-up data.
Main Results:
- No significant difference in epicardial coronary stenosis between 76 HCM patients and 152 controls after matching.
- Markedly greater AMR in the three epicardial coronary arteries of HCM patients.
- 65.7% of HCM patients met the criterion (AMR ≥ 250 mmHg*s/m) for coronary microvascular dysfunction (CMD).
- Increased left ventricular wall thickness was an independent risk factor for CMD (OR=1.209).
- Higher AMR in the left anterior descending artery (AMR_LAD ≥ 250 mmHg*s/m) predicted increased cumulative risk of adverse endpoints (log-rank p=0.023) and was an independent risk factor (HR=11.64).
Conclusions:
- Angiography-derived microcirculatory resistance (AMR) is a valuable tool for assessing microvascular dysfunction in HCM.
- Coronary microvascular dysfunction is prevalent in HCM patients with chest pain.
- AMR provides significant prognostic insights, with higher values indicating increased risk of adverse clinical outcomes.
Abstract:
Chest pain, a common initial symptom in hypertrophic cardiomyopathy (HCM) patients, is closely linked to myocardial ischemia, despite the absence of significant coronary artery stenosis. This study explored microvascular dysfunction in HCM patients by employing angiography-derived microcirculatory resistance (AMR) as a novel tool for comprehensive assessment. This retrospective analysis included HCM patients with chest pain as the primary symptom and control patients without cardiac hypertrophy during the same period. The AMR was computed through angiography, providing a wire-free and adenosine-free index for evaluating microcirculatory function. Propensity score matching ensured balanced demographics between groups. This study also investigated the correlation between the AMR and clinical outcomes by utilizing echocardiography and follow-up data. After matching, 76 HCM patients and 152 controls were analyzed. While there was no significant difference in the incidence of epicardial coronary stenosis, the AMR of three epicardial coronary arteries was markedly greater in HCM patients. The criterion of an AMR ≥ 250 mmHg*s/m was that 65.7% of HCM patients experienced coronary microvascular dysfunction (CMD). Independent risk factors for CMD included increased left ventricular (LV) wall thickness (OR = 1.209, 95% CI 1.013-1.443, p = 0.036). Furthermore, an AMR_LAD ≥ 250 mmHg*s/m had an increased cumulative risk of the endpoint (log-rank p = 0.023) and was an independent risk factor for the endpoint (HR = 11.64, 95% CI 1.13-120.03, p = 0.039), providing valuable prognostic insights.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

